CSL Behring Announces Expansion of Illinois Facility

According to an article today via Market Watch, CSL Behring is expanding. The organization, which specializes in producing therapies around the world to treat coagulation disorders including hemophilia and von Willebrand disease, will expand its facility in Kankakee, Illinois. It will increase their plasma processing and albumin production capacity their Illinois facility. According to the company, the expansion is necessary due to the growing worldwide demand for CSL Behring’s immunoglobulins and albumin.

“CSL Behring is committed to serving patients with rare diseases in all corners of the world,” CSL Behring’s Executive Vice President Global Operations and Planning, Mary Sontrop said, “In today’s competitive market, we continually explore the latest technology that’s available, and evaluate how it can make our operations and physical plant more efficient to meet patients’ growing needs. Increasing Kankakee’s ability to fractionate plasma and produce albumin and intermediate paste is an important step for our global operations.”

The expansion is expected after the Food and Drug Administration (FDA) recently approved it.

Photo Credit – CSL Behring

webleed.org – your source for bleeding news!